NCT06274515 2026-04-06
REMERGE
Hoffmann-La Roche
Phase 4 Recruiting
Clinical Trials
28 trialsNCT05191940 2026-03-20
LAPC
EBG MedAustron GmbH
Phase NA Recruiting
NCT06492122 2026-01-29
ProTACT
Full-Life Technologies GmbH
Phase 1 Recruiting
NCT05854368 2025-05-16
PREGASIGN#1
Institut Pasteur
Phase NA Recruiting
NCT04875871 2025-05-11
PARTICLE-PATHY
EBG MedAustron GmbH
Phase NA Terminated
NCT06703632 2025-02-27
MS-Prevecol
ADVANCED MARKER DISCOVERY S.L.
Phase NA Recruiting
NCT02274662 2025-01-16
Expanded Access Protocol Thymus Transplantation
Sumitomo Pharma Switzerland GmbH
Phase 4 Completed
NCT06738511 2024-12-17
Validation of a Molecular Signature for Early Detection of Colorectal Cancer
ADVANCED MARKER DISCOVERY S.L.
Phase NA Completed
NCT06033183 2024-11-22
FOCUSO
Neolys
Phase NA Recruiting
NCT05133128 2024-02-22
IMMUNOPBMC
Servier
Phase NA Terminated
NCT04180176 2024-01-17
PCG
Genentech, Inc.
Phase 4 Completed
NCT03860207 2023-09-13
Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers
Y-mAbs Therapeutics
Phase 1/2 Terminated
NCT03371420 2023-04-18
PET Imaging of Subjects Using 124I-PU-AD
Samus Therapeutics, Inc.
Phase EARLY_PHASE1 Terminated
NCT05251376 2023-01-19
Study of LYN-014 in Individuals With Opioid Use Disorder Who Are Stable on Methadone Therapy
Lyndra Inc.
Phase 1 Withdrawn
NCT04515043 2021-06-01
EXPLORATORY STUDY Addendum to INVAC1-CT-101 (NCT02301754)
Invectys
Phase 1 Completed
NCT03355820 2020-11-19
A Follow-up Extension Study to Evaluate the Persistence of Immune Response to GSK Biologicals' HPV Vaccine in Healthy Chinese Female Subjects Who Received Three Doses of the Vaccine in the HPV-058 Study
GlaxoSmithKline
Phase 3 Completed
NCT00947115 2020-10-30
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects
GlaxoSmithKline
Phase 3 Completed
NCT00877877 2020-01-18
Evaluation of Long-term Immunogenicity and Safety of a Human Papillomavirus (HPV) Vaccine in Healthy Female Subjects.
GlaxoSmithKline
Phase 3 Completed
NCT00685750 2019-06-20
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
GlaxoSmithKline
Phase NA Terminated
NCT00518336 2016-12-09
Follow-up Study to Evaluate the Long-term Efficacy of the HPV Vaccine (580299) in Healthy Young Adult Women in Brazil
GlaxoSmithKline
Phase 2 Completed
NCT00929526 2016-10-20
Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study
GlaxoSmithKline
Phase 3 Completed
NCT01521780 2015-11-02
Characterization of Baseline Biomarker Variability in Participants With Hepatocellular Carcinoma (MK-0000-215)
Merck Sharp & Dohme LLC
Phase 1 Terminated
NCT02100618 2015-07-20
Antibody Persistence for GlaxoSmithKline (GSK) Biologicals' HPV-16/18 L1 VLP AS04 Vaccine (GSK-580299) Administered in Healthy Adults and Adolescents, 6.5 Years After First Vaccination in the Primary Study
GlaxoSmithKline
Phase 3 Withdrawn
NCT01071837 2015-06-16
APG101 in Glioblastoma
Apogenix AG
Phase 2 Completed
NCT01329718 2014-08-04
SPR0012
Epigenomics, Inc
Phase EARLY_PHASE1 Completed
NCT01209013 2012-05-08
Oedisse
Pinnacle Biologics Inc.
Phase 3 Withdrawn
NCT00436189 2008-04-30
Assess Cancer in Ovarian Tumors With Biomarkers.
Ciphergen Biosystems
Phase NA Completed
NCT00140036 2008-03-03
Pharmacogenomics Blood Sampling Protocol For Irinotecan/Fluorouracil/Leucovorin(CPT-11/FU/LV).
Pfizer
Phase 4 Completed